Kancera changes Certified Adviser to Redeye AB
Kancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.
Read MoreKancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.
Read MoreKancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio’s phase III ready dutogliptin program and Kancera’s fractalkine program in phase II...
Read MoreThe period in brief – financial summary for the fourth quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 8,5 million (SEK 17,1 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the third quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 10,2 million (SEK 9,2 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the second quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 9,7 million (SEK 16,5 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...
Read MoreThe board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders and which was covered by subscription and guarantee commitments...
Read MoreKancera AB (”Kancera” or the ”Company”) announced on February 23, 2024, that the board of directors has resolved to carry out a new issue of shares with preferential rights for existing shareholders in the Company, corresponding to approximately SEK...
Read MoreThe board of directors of Kancera AB (”Kancera” or the ”Company”), has today, based on the issue authorization from the annual general meeting held on May 25, 2023, resolved on a new share issue with preferential rights for the...
Read MoreThe period in brief – financial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 17,1 million (SEK 11,6 million). Operating income amounted to SEK -18,5 million (SEK -14,0...
Read More